tradingkey.logo

Johnson & Johnson

JNJ
View Detailed Chart
206.650USD
-0.840-0.40%
Market hours ETQuotes delayed by 15 min
497.24BMarket Cap
19.80P/E TTM

Johnson & Johnson

206.650
-0.840-0.40%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.40%

5 Days

-0.14%

1 Month

+2.34%

6 Months

+33.09%

Year to Date

-0.14%

1 Year

+41.32%

View Detailed Chart

TradingKey Stock Score of Johnson & Johnson

Currency: USD Updated: 2026-01-07

Key Insights

Johnson & Johnson's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 47 out of 158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 209.96.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Johnson & Johnson's Score

Industry at a Glance

Industry Ranking
47 / 158
Overall Ranking
115 / 4544
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

49°C

Very Low
Very High
Negative

Johnson & Johnson Highlights

StrengthsRisks

Johnson & Johnson is an American multinational corporation specializing in pharmaceuticals, biotechnology, and medical technologies, headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange (NYSE:JNJ). Its common stock is part of the Dow Jones Industrial Average, and the company is ranked No. 42 on the 2024 Fortune 500 list of the largest corporations in the United States. In 2024, it was ranked 45th on the Forbes Global 2000 list. Johnson & Johnson employs approximately 138,000 individuals globally, led by its current chairman and CEO, Joaquin Duato.

Founded in 1886 by three brothers—Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson—the company initially focused on selling ready-to-use sterile surgical dressings. In 2023, the firm spun off its consumer healthcare business segment into a new publicly traded entity, Kenvue, allowing it to concentrate solely on the development and manufacturing of pharmaceutical prescription drugs and medical device technologies.

Johnson & Johnson is recognized as one of the most valuable companies worldwide and is one of only two U.S.-based corporations possessing a prime credit rating of AAA.

Industry Leader
The company's revenue leads the industry, with the latest annual revenue totaling USD 88.82B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 84.05%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 84.05%.
Fairly Valued
The company’s latest PE is 19.88, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.81B shares, decreasing 0.12% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 59.18K shares of this stock.

Analyst Rating

Based on 28 analysts
Buy
Current Rating
209.956
Target Price
+2.76%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Johnson & Johnson Info

Johnson & Johnson is an American multinational corporation specializing in pharmaceuticals, biotechnology, and medical technologies, headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange (NYSE:JNJ). Its common stock is part of the Dow Jones Industrial Average, and the company is ranked No. 42 on the 2024 Fortune 500 list of the largest corporations in the United States. In 2024, it was ranked 45th on the Forbes Global 2000 list. Johnson & Johnson employs approximately 138,000 individuals globally, led by its current chairman and CEO, Joaquin Duato.

Founded in 1886 by three brothers—Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson—the company initially focused on selling ready-to-use sterile surgical dressings. In 2023, the firm spun off its consumer healthcare business segment into a new publicly traded entity, Kenvue, allowing it to concentrate solely on the development and manufacturing of pharmaceutical prescription drugs and medical device technologies.

Johnson & Johnson is recognized as one of the most valuable companies worldwide and is one of only two U.S.-based corporations possessing a prime credit rating of AAA.

Ticker SymbolJNJ
CompanyJohnson & Johnson
CEODuato (Joaquin Boix)
Websitehttps://www.jnj.com/

FAQs

What is the current price of Johnson & Johnson (JNJ)?

The current price of Johnson & Johnson (JNJ) is 206.650.

What is the symbol of Johnson & Johnson?

The ticker symbol of Johnson & Johnson is JNJ.

What is the 52-week high of Johnson & Johnson?

The 52-week high of Johnson & Johnson is 215.185.

What is the 52-week low of Johnson & Johnson?

The 52-week low of Johnson & Johnson is 140.680.

What is the market capitalization of Johnson & Johnson?

The market capitalization of Johnson & Johnson is 497.24B.

What is the net income of Johnson & Johnson?

The net income of Johnson & Johnson is 14.07B.

Is Johnson & Johnson (JNJ) currently rated as Buy, Hold, or Sell?

According to analysts, Johnson & Johnson (JNJ) has an overall rating of Buy, with a price target of 209.956.

What is the Earnings Per Share (EPS TTM) of Johnson & Johnson (JNJ)?

The Earnings Per Share (EPS TTM) of Johnson & Johnson (JNJ) is 10.435.
KeyAI